WO1994025012A3 - Medicaments for treatment of migraine, epilepsy and feeding disorders - Google Patents

Medicaments for treatment of migraine, epilepsy and feeding disorders Download PDF

Info

Publication number
WO1994025012A3
WO1994025012A3 PCT/EP1994/001240 EP9401240W WO9425012A3 WO 1994025012 A3 WO1994025012 A3 WO 1994025012A3 EP 9401240 W EP9401240 W EP 9401240W WO 9425012 A3 WO9425012 A3 WO 9425012A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
migraine
epilepsy
medicaments
feeding disorders
Prior art date
Application number
PCT/EP1994/001240
Other languages
French (fr)
Other versions
WO1994025012A2 (en
Inventor
Thomas Paul Blackburn
Guy Anthony Kennett
Gordon Smith Baxter
Original Assignee
Smithkline Beecham Plc
Thomas Paul Blackburn
Guy Anthony Kennett
Gordon Smith Baxter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Thomas Paul Blackburn, Guy Anthony Kennett, Gordon Smith Baxter filed Critical Smithkline Beecham Plc
Priority to AU65697/94A priority Critical patent/AU6569794A/en
Publication of WO1994025012A2 publication Critical patent/WO1994025012A2/en
Publication of WO1994025012A3 publication Critical patent/WO1994025012A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

A novel method of medical treatment, in particular the treatment and prevention of epilepsy and migraine.
PCT/EP1994/001240 1993-04-28 1994-04-20 Medicaments for treatment of migraine, epilepsy and feeding disorders WO1994025012A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65697/94A AU6569794A (en) 1993-04-28 1994-04-20 Medicaments for treatment of migraine, epilepsy and feeding disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9308802.9 1993-04-28
GB939308802A GB9308802D0 (en) 1993-04-28 1993-04-28 Treatment

Publications (2)

Publication Number Publication Date
WO1994025012A2 WO1994025012A2 (en) 1994-11-10
WO1994025012A3 true WO1994025012A3 (en) 1994-12-22

Family

ID=10734635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/001240 WO1994025012A2 (en) 1993-04-28 1994-04-20 Medicaments for treatment of migraine, epilepsy and feeding disorders

Country Status (4)

Country Link
AU (1) AU6569794A (en)
GB (1) GB9308802D0 (en)
WO (1) WO1994025012A2 (en)
ZA (1) ZA942809B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
GB9700899D0 (en) * 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP4636486B2 (en) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション Arylurea with angiogenesis inhibitory activity
ES2305808T3 (en) 2003-05-20 2008-11-01 Bayer Healthcare Llc DIARILURES WITH INHIBITING ACTIVITY OF QUINASAS.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (en) * 1990-09-13 1992-04-02 Beecham Group Plc Indole ureas as 5 ht receptor antagonist
WO1993018028A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (en) * 1990-09-13 1992-04-02 Beecham Group Plc Indole ureas as 5 ht receptor antagonist
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
WO1993018028A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
G.A.KENNETT ET AL.: "In vivo properties of SB 200646A, a 5-HT 2c/2b receptor antagonist", BR.J.PHARMACOL., vol. 111, no. 3, March 1994 (1994-03-01), pages 797 - 802 *
H.O.KALKMAN ET AL.: "MIGRAINE PROPHYLAXIS BY 5HT2B RECEPTOR BLOCKADE?", PHARMACOL.TOXICOL., vol. 72, no. SUP2, 1993 *
H.O.KALKMAN: "IS MIGRAINE PROPHYLACTIC ACTIVITY CAUSED BY 5-HT 2B OR 5-HT 2C RECEPTOR BLOCKADE ?", LIFE SCI., vol. 54, no. 10, 1994, pages 641 - 644 *
I.T.FORBES ET AL.: "N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea Hydrochloride: The First Selective 5-HT1c receptor Antagonist", J.MED.CHEM., vol. 36, no. 8, 16 April 1993 (1993-04-16), pages 1104 - 1107 *
K.SCHMUCK ET AL.: "Cloning and functional characterization of the human 5-HT 2B serotonin receptor", FEBS LETT., vol. 342, no. 1, 28 March 1994 (1994-03-28), pages 85 - 90 *
P-FLUDZINSKI ET AL.: "2,3-Dialkyl(dimethylamino)indoles: Interaction with 5HT1, 5HT2, and Rat Stomach Fundal Serotonin Receptors", J.MED.CHEM., vol. 29, no. 11, November 1986 (1986-11-01), pages 2415 - 2418 *
Z.AUSTIN: "The Serotonin System, Part I: Clinical Significance", CAN.J.HOSP.PHARM., vol. 45, no. 5, October 1992 (1992-10-01), pages 183 - 186 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors

Also Published As

Publication number Publication date
WO1994025012A2 (en) 1994-11-10
GB9308802D0 (en) 1993-06-09
AU6569794A (en) 1994-11-21
ZA942809B (en) 1995-10-23

Similar Documents

Publication Publication Date Title
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
WO1997034586A3 (en) Device and method for treating ophthalmic diseases
AU3432989A (en) Product and method for the treatment of acne etc.
AU4959293A (en) Microparticle preparations made from biodegradable copolymers
AU1513395A (en) Medical infusion apparatus including safety valve
HUP9600549A3 (en) N-(3-benzofuranyl)urea-derivatives, medicaments containing the same and process for producing them
GB2333453A (en) Colostrinin and uses thereof
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
AU6520296A (en) Method and apparatus for monitoring and/or controlling the neuromuscular blocking, specially the blocking produced by muscular relaxing pharmaceuticals used during anaesthesia
EP0675120A3 (en) Use of ascorbyl-gamma-linolenate or a ascorbyl-dihomo-gamma-linolenate for the treatment of asthma, cancer, cardiovascular and inflammatory disorders
AU2465695A (en) Structure forming method, apparatus and the resulting product
AU4705193A (en) Medicaments for the treatment or prevention of elevated intraocular pressure
IL112602A0 (en) N,n-dimethyl-1-Ú1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine in the treatment of epilepsy
ZA975510B (en) Method for increasing the anti-wettability of a body, body treated in this way and applications thereof.
WO1994025012A3 (en) Medicaments for treatment of migraine, epilepsy and feeding disorders
EP1106609A3 (en) Aminoalcohol derivative and medicament comprising the same
WO1997012963A3 (en) A paf-acetylhydrolase and use in therapy
GR3021203T3 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane.
EP0657438A3 (en) Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones.
EP0622369A3 (en) 2-Amino-4-quinoline-dihydropyridine, process for preparation and use thereof.
AU6772294A (en) Continuous feed, low pressure process and apparatus for manufacturing thermoplastic posts
AU4984493A (en) Injection for curing injured abnormal tissue, process for producing the same, and use thereof
GR950100091A (en) Method for the treatment of plants.
HUT71793A (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives, pharmaceutical compns. contg. them and process for producing the said compds.
HUP9601701A2 (en) Aromatic hydroxamic acid compounds, process for producing them and their use pharmaceutical compns. contg. them and process for producing the said compds.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA